GW appoints president for US and relocates CEO
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals, a biopharmaceutical company developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, has appointed Julian Gangolli president, North America. Mr Gangolli was most recently president of the North American pharmaceutical division of Allergan, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8bn in 2014.